The Cochlear Ltd (ASX: COH) share price is in focus today after the company reported FY25 sales revenue up 4% to $2,356 million and a 9% jump in statutory net profit to $389 million, with a 5% increase in full-year dividends.
Image source: Getty Images
What did Cochlear report?
- Sales revenue rose 4% to $2,356 million
- Statutory net profit up 9% to $389 million
- Underlying net profit increased 1% to $392 million, margin steady at 17%
- Final dividend of $2.15 per share, full-year dividend up 5% to $4.30 per share (72% payout)
- Cochlear implants shipped: 53,968 units, up 12%
- FY26 underlying net profit guidance: $435–460 million, up 11–17%
What else happened in FY25?
Cochlear launched the Nucleus Nexa System, the world's first smart cochlear implant system with upgradeable firmware, following a two-decade R&D investment. This innovation is rolling out globally and is expected to expand market reach, with early strong demand in Europe and Australia.
While cochlear and acoustics implant revenue continued to grow, services revenue declined, partly due to a slowdown in sound processor upgrades after high initial uptake in previous years. The company also made strong progress on sustainability, achieving 99% renewable energy usage at manufacturing sites.
What did Cochlear management say?
Commenting on the result, CEO and President Dig Howitt said:
We remain confident of the opportunity to grow our markets. There remains a significant, unmet and addressable clinical need for cochlear and acoustic implants that is expected to continue to underpin the long-term sustainable growth of the business.
What's next for Cochlear?
Looking to FY26, Cochlear expects to help over 60,000 people hear with its implants and has guided for an 11–17% lift in underlying net profit. The launch of the Nucleus Nexa System in developed markets and further product rollouts are set to drive growth, with overall revenue and earnings weighted to the second half.
The company plans to maintain investment in R&D and market access, continue sustainable operations, and buy back up to $75 million of shares over the next year. Net cash is expected to recover with reduced working capital levels, and dividends are set to remain strong.
Cochlear share price snapshot
Over the past 12 months, the Cochlear has trailed the market. Cochlear shares have declined 2%, while the S&P/ASX 200 Index (ASX: XJO) has risen 13%.
